Cerebral atherosclerosis (CA) is a slowly progressive brain dysfunction caused by diffuse and / or small-focal brain tissue damage in conditions of long-standing cerebral insufficiency.

The aim of our study is a comprehensive analysis of the effectiveness and safety assessment of the course of taking the aminophenylbutyric acid in patients with CA and type 2 diabetes (T2D) as an adjuvant to the basic therapy used in Ukraine in accordance with the standards of patients with this pathology: 1 tablet (250 mg) 2 times a day for a month. This clinical study was conducted as a supervisory (non-interventional), open-label, controlled, randomized, prospective study in which aminophenylbutyric acid (APBA) was administered according to registered indications.

The study involved 26 patients (mean age = 43±6 years) – 5 men and 21 women who were treated at the State Institution «V.P.Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine» concerning T2D in a state of subcompensation with CA.

It has been found that in patients with CA and T2D, under the influence of a course of treatment with APBA, cognitive functions are activated (increases attention and improves memory) and emotional sphere is improved (the level of anxiety decreases), and there is a relative vasoactive effect on cerebral hemodynamics (peripheral resistance decreases in separate vessels of carotid and vertebral basilar pools). According to spectral and temporal analysis of heart rate variability, APBA harmonizes sympatho-parasympathetic balance in patients with CA and T2D. The positive effect of APBA on neuropsychological functions, cerebral blood flow and heart rate variability gives grounds to recommend this drug in the scheme of complex treatment of patients with CA and T2D.